首页 > 最新文献

BMJ Open Gastroenterology最新文献

英文 中文
Investigating the role of iron status in the development of coeliac disease: a Mendelian randomisation study. 调查铁元素在乳糜泻发病中的作用:孟德尔随机研究。
IF 3.1 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-04 DOI: 10.1136/bmjgast-2023-001236
Isabel A Hujoel, Margaux Louise Anna Hujoel

Objective: The environmental trigger behind the increasing prevalence of coeliac disease is not known. One suggested cause is iron deficiency, which is common in coeliac disease. We aimed to evaluate this possible association with Mendelian randomisation (MR), which under certain assumptions can suggest a causal relationship.

Design: We conducted a two-sample MR study examining the relationship between single nucleotide polymorphisms (SNPs) associated with iron status and the presence of coeliac disease. The SNPs were drawn from a meta-analysis of three genome-wide association studies (GWAS). The association between these SNPs and coeliac disease was assessed using GWAS summary statistics from the UK Biobank. This consists of 336 638 white British individuals, 1855 with coeliac disease. We performed an MR Egger test for pleiotropy and assessed the plausibility of the assumptions of MR to evaluate for possible causality.

Results: There were four SNPs strongly associated with systemic iron status. These were not associated with known risk factors for coeliac disease. All four SNPs were available in the UK Biobank coeliac disease summary statistics. Harmonising exposure and outcome associations, we found that higher iron status was negatively associated with risk of coeliac disease (OR per 1 SD increase in serum iron: 0.65, 95% CI 0.47 to 0.91). Leave-one-out analyses had consistent results, and no single SNP drove the association. All three assumptions of MR appeared plausible.

Conclusion: We found that genetically lower iron levels were associated with an increased risk of coeliac disease. Our findings highlight a potential opportunity for coeliac disease prevention.

目的:乳糜泻发病率不断上升的环境诱因尚不清楚。其中一个原因是缺铁,而缺铁在乳糜泻中很常见。我们的目的是利用孟德尔随机化(Mendelian randomisation,MR)评估这种可能的关联:设计:我们进行了一项双样本 MR 研究,考察了与铁状况相关的单核苷酸多态性(SNPs)与是否患有乳糜泻之间的关系。这些 SNPs 来自于对三项全基因组关联研究(GWAS)的荟萃分析。这些 SNP 与乳糜泻之间的关系是通过英国生物库的 GWAS 统计摘要进行评估的。该数据库由 336 638 名英国白人组成,其中 1855 人患有乳糜泻。我们对多向性进行了MR Egger检验,并评估了MR假设的合理性,以评估可能的因果关系:结果:有四个 SNP 与全身铁状况密切相关。结果:有四个 SNP 与全身铁状况密切相关,但与已知的乳糜泻风险因素无关。所有四个 SNP 均可在英国生物库的乳糜泻疾病汇总统计中找到。将暴露与结果的相关性统一起来,我们发现,较高的铁状态与罹患乳糜泻的风险呈负相关(血清铁每增加 1 SD 的 OR:0.65,95% CI 0.47 至 0.91)。剔除分析的结果是一致的,没有一个SNP导致这种关联。MR的所有三个假设似乎都是可信的:我们发现,基因铁水平较低与罹患乳糜泻的风险增加有关。我们的发现凸显了预防乳糜泻的潜在机会。
{"title":"Investigating the role of iron status in the development of coeliac disease: a Mendelian randomisation study.","authors":"Isabel A Hujoel, Margaux Louise Anna Hujoel","doi":"10.1136/bmjgast-2023-001236","DOIUrl":"10.1136/bmjgast-2023-001236","url":null,"abstract":"<p><strong>Objective: </strong>The environmental trigger behind the increasing prevalence of coeliac disease is not known. One suggested cause is iron deficiency, which is common in coeliac disease. We aimed to evaluate this possible association with Mendelian randomisation (MR), which under certain assumptions can suggest a causal relationship.</p><p><strong>Design: </strong>We conducted a two-sample MR study examining the relationship between single nucleotide polymorphisms (SNPs) associated with iron status and the presence of coeliac disease. The SNPs were drawn from a meta-analysis of three genome-wide association studies (GWAS). The association between these SNPs and coeliac disease was assessed using GWAS summary statistics from the UK Biobank. This consists of 336 638 white British individuals, 1855 with coeliac disease. We performed an MR Egger test for pleiotropy and assessed the plausibility of the assumptions of MR to evaluate for possible causality.</p><p><strong>Results: </strong>There were four SNPs strongly associated with systemic iron status. These were not associated with known risk factors for coeliac disease. All four SNPs were available in the UK Biobank coeliac disease summary statistics. Harmonising exposure and outcome associations, we found that higher iron status was negatively associated with risk of coeliac disease (OR per 1 SD increase in serum iron: 0.65, 95% CI 0.47 to 0.91). Leave-one-out analyses had consistent results, and no single SNP drove the association. All three assumptions of MR appeared plausible.</p><p><strong>Conclusion: </strong>We found that genetically lower iron levels were associated with an increased risk of coeliac disease. Our findings highlight a potential opportunity for coeliac disease prevention.</p>","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":"11 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10773400/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139097304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Does Hispanic ethnicity play a role in outcomes for diverticular surgery in the USA? 在美国,西班牙裔对憩室手术的结果有影响吗?
IF 3.1 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-12-02 DOI: 10.1136/bmjgast-2023-001215
Jesse K Kelley, Kathrine Kelly, Charles Reed, Nathan Winkler, Jessica Parker, James Ogilvie

Objective: The aim of this study is to investigate whether origins of ethnicity affect the outcomes of surgery for diverticulitis in the USA.

Design: The American College of Surgeons National Surgical Quality Improvement Programme database from 2008 to 2017 was used to identify patients undergoing colectomy for diverticulitis. Patient demographics, comorbidities, procedural details and outcomes were captured and compared by ethnicity status.

Results: A total of 375 311 surgeries for diverticulitis were included in the final analysis. The average age of patients undergoing surgery for diverticulitis remained consistent over the time frame of the study (62 years), although the percentage of younger patients (age 18-39 years) rose slightly from 7.8% in 2008 to 8.6% in 2017. The percentage of surgical patients with Hispanic ethnicity increased from 3.7% in 2008 to 6.6% of patients in 2017. Hispanic patients were younger than their non-Hispanic counterparts (57 years vs 62 years, p<0.01) at time of surgery. There were statistically significant differences in the proportion of laparoscopic cases (51% vs 49%, p<0.01), elective cases (62% vs 66%, p<0.01) and the unadjusted rate of postoperative mortality (2.8% vs 3.4%, p<0.01) between Hispanic patients compared with non-Hispanic patients, respectively. Multivariable logistic regression models did not identify Hispanic ethnicity as a significant predictor for increased morbidity (p=0.13) or mortality (p=0.80).

Conclusion: Despite a significant younger population undergoing surgery for diverticulitis, Hispanic ethnicity was not associated with increased rates of emergent surgery, open surgery or postoperative complications compared with a similar non-Hispanic population.

目的:本研究的目的是调查种族起源是否影响美国憩室炎手术的结果。设计:使用2008年至2017年美国外科医师学会国家手术质量改进计划数据库来识别因憩室炎接受结肠切除术的患者。患者人口统计、合并症、手术细节和结果被捕获并按种族状况进行比较。结果:本组共纳入375311例憩室炎手术。憩室炎手术患者的平均年龄在研究期间(62岁)保持一致,尽管年轻患者(18-39岁)的比例从2008年的7.8%略微上升到2017年的8.6%。西班牙裔手术患者的比例从2008年的3.7%上升到2017年的6.6%。西班牙裔患者比非西班牙裔患者年轻(57岁vs 62岁)。结论:尽管接受憩室炎手术的人群明显更年轻,但与类似的非西班牙裔人群相比,西班牙裔与急诊手术、开放手术或术后并发症的发生率增加无关。
{"title":"Does Hispanic ethnicity play a role in outcomes for diverticular surgery in the USA?","authors":"Jesse K Kelley, Kathrine Kelly, Charles Reed, Nathan Winkler, Jessica Parker, James Ogilvie","doi":"10.1136/bmjgast-2023-001215","DOIUrl":"10.1136/bmjgast-2023-001215","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study is to investigate whether origins of ethnicity affect the outcomes of surgery for diverticulitis in the USA.</p><p><strong>Design: </strong>The American College of Surgeons National Surgical Quality Improvement Programme database from 2008 to 2017 was used to identify patients undergoing colectomy for diverticulitis. Patient demographics, comorbidities, procedural details and outcomes were captured and compared by ethnicity status.</p><p><strong>Results: </strong>A total of 375 311 surgeries for diverticulitis were included in the final analysis. The average age of patients undergoing surgery for diverticulitis remained consistent over the time frame of the study (62 years), although the percentage of younger patients (age 18-39 years) rose slightly from 7.8% in 2008 to 8.6% in 2017. The percentage of surgical patients with Hispanic ethnicity increased from 3.7% in 2008 to 6.6% of patients in 2017. Hispanic patients were younger than their non-Hispanic counterparts (57 years vs 62 years, p<0.01) at time of surgery. There were statistically significant differences in the proportion of laparoscopic cases (51% vs 49%, p<0.01), elective cases (62% vs 66%, p<0.01) and the unadjusted rate of postoperative mortality (2.8% vs 3.4%, p<0.01) between Hispanic patients compared with non-Hispanic patients, respectively. Multivariable logistic regression models did not identify Hispanic ethnicity as a significant predictor for increased morbidity (p=0.13) or mortality (p=0.80).</p><p><strong>Conclusion: </strong>Despite a significant younger population undergoing surgery for diverticulitis, Hispanic ethnicity was not associated with increased rates of emergent surgery, open surgery or postoperative complications compared with a similar non-Hispanic population.</p>","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":"10 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693875/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138482028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Naturally nutrient rich (NNR) score and the risk of colorectal cancer: a case-control study. 自然营养丰富(NNR)评分与结直肠癌风险:一项病例对照研究。
IF 3.1 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-12-02 DOI: 10.1136/bmjgast-2023-001242
Naeemeh Hassanpour Ardekanizadeh, Mahdi Mousavi Mele, Saeideh Mohammadi, Soheila Shekari, Mobina Zeinalabedini, Mohammad Masoumvand, Seyedeh Hayedeh Mousavi Shalmani, Seyed Ali Askarpour, Maryam Gholamalizadeh, Farhad Vahid, Saeid Doaei

Background: The association between colorectal cancer (CRC) and nutrients has been studied frequently. However, the association of nutrient density of diets with the risk of CRC has been less studied. This study aimed to investigate the association between CRC and naturally nutrient rich (NNR) score in Iranian adults.

Method: This case-control study included 160 patients with colorectal cancer and 320 controls aged 35-70 years in Tehran, Iran. Dietary intake was assessed using a 168-item food frequency questionnaire. The NNR score was obtained by calculating the average daily value of 14 nutrients including protein, vitamins A, C, D, E, B1, B2, B12, calcium, zinc, iron, folate, potassium and unsaturated fatty acids.

Results: Regarding dietary intake of the components of NNR score, the case group had a lower intake of polyunsaturated fat (15.41±4.44 vs 16.54±4.20 g/day, p=0.01), vitamin E (10.15±4.16 vs 13.1±5.33; p=0.001), vitamin B1 (2±0.86 vs 2.19±0.84 mg/day, p=0.03) and folate (516.45±96.59 vs 571.05±80.31; p=0.001) and a higher intake of oleic acid (8.21±5.46 vs 5.59±3.17 g/day, p=0.01) compared with the control group. Colorectal cancer risk was inversely associated with the NNR score after adjusting for the confounders (OR 0.92; 95% CI 0.88 to 0.97; p=0.03).

Conclusion: Low NNR scores may be linked to CRC. If confirmed by future longitudinal research, this result may help prevent CRC by recommending nutrient-rich diets.

背景:人们经常研究结直肠癌(CRC)与营养物质之间的关系。然而,饮食营养密度与结直肠癌风险之间的关系研究较少。本研究旨在调查伊朗成年人CRC与自然营养丰富(NNR)评分之间的关系。方法:本病例对照研究纳入了伊朗德黑兰年龄在35-70岁之间的160例结直肠癌患者和320例对照患者。膳食摄入量评估采用168项食物频率问卷。NNR评分是通过计算蛋白质、维生素A、C、D、E、B1、B2、B12、钙、锌、铁、叶酸、钾和不饱和脂肪酸等14种营养素的日均摄入量得出的。结果:在NNR评分组分的膳食摄入量方面,病例组多不饱和脂肪(15.41±4.44 vs 16.54±4.20 g/d, p=0.01)、维生素E(10.15±4.16 vs 13.1±5.33;p=0.001)、维生素B1(2±0.86 vs 2.19±0.84 mg/d, p=0.03)和叶酸(516.45±96.59 vs 571.05±80.31;P =0.001)和较高的油酸摄入量(8.21±5.46 g/d vs 5.59±3.17 g/d, P =0.01)。校正混杂因素后,结直肠癌风险与NNR评分呈负相关(OR 0.92;95% CI 0.88 ~ 0.97;p = 0.03)。结论:低NNR评分可能与结直肠癌有关。如果未来的纵向研究证实,这一结果可能有助于通过推荐营养丰富的饮食来预防结直肠癌。
{"title":"Naturally nutrient rich (NNR) score and the risk of colorectal cancer: a case-control study.","authors":"Naeemeh Hassanpour Ardekanizadeh, Mahdi Mousavi Mele, Saeideh Mohammadi, Soheila Shekari, Mobina Zeinalabedini, Mohammad Masoumvand, Seyedeh Hayedeh Mousavi Shalmani, Seyed Ali Askarpour, Maryam Gholamalizadeh, Farhad Vahid, Saeid Doaei","doi":"10.1136/bmjgast-2023-001242","DOIUrl":"10.1136/bmjgast-2023-001242","url":null,"abstract":"<p><strong>Background: </strong>The association between colorectal cancer (CRC) and nutrients has been studied frequently. However, the association of nutrient density of diets with the risk of CRC has been less studied. This study aimed to investigate the association between CRC and naturally nutrient rich (NNR) score in Iranian adults.</p><p><strong>Method: </strong>This case-control study included 160 patients with colorectal cancer and 320 controls aged 35-70 years in Tehran, Iran. Dietary intake was assessed using a 168-item food frequency questionnaire. The NNR score was obtained by calculating the average daily value of 14 nutrients including protein, vitamins A, C, D, E, B<sub>1</sub>, B<sub>2</sub>, B<sub>12</sub>, calcium, zinc, iron, folate, potassium and unsaturated fatty acids.</p><p><strong>Results: </strong>Regarding dietary intake of the components of NNR score, the case group had a lower intake of polyunsaturated fat (15.41±4.44 vs 16.54±4.20 g/day, p=0.01), vitamin E (10.15±4.16 vs 13.1±5.33; p=0.001), vitamin B<sub>1</sub> (2±0.86 vs 2.19±0.84 mg/day, p=0.03) and folate (516.45±96.59 vs 571.05±80.31; p=0.001) and a higher intake of oleic acid (8.21±5.46 vs 5.59±3.17 g/day, p=0.01) compared with the control group. Colorectal cancer risk was inversely associated with the NNR score after adjusting for the confounders (OR 0.92; 95% CI 0.88 to 0.97; p=0.03).</p><p><strong>Conclusion: </strong>Low NNR scores may be linked to CRC. If confirmed by future longitudinal research, this result may help prevent CRC by recommending nutrient-rich diets.</p>","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":"10 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693883/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138482029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
People with IBD evidence more microarousals during sleep architecture assessments 在睡眠结构评估过程中,IBD 患者会出现更多的微动
IF 3.1 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-12-01 DOI: 10.1136/bmjgast-2023-001249
Jessica K Salwen-Deremer, Matthew J Reid, Sarah J Westvold, Corey A Siegel, Michael T Smith
Objective Poor sleep is common in inflammatory bowel disease (IBD) and may be associated with overall worse disease outcomes. While the sleep/IBD literature is growing, the data are often self-reported. Further, much of the research using objective measures of sleep architecture, or the overall pattern of sleep depth, rely on single-night assessments, which can be of questionable validity. Design Participants with IBD and healthy controls were recruited from Dartmouth-Hitchcock Medical Center as part of a two-phase clinical trial. Sleep architecture was assessed using three nights of in-home electroencephalographic monitoring and scored according to the American Academy of Sleep Medicine guidelines. Results Our sample included 15 participants with IBD and 8 healthy controls. Participants with IBD were more psychiatrically complex, with more self-reported insomnia, anxiety and depression. Participants with IBD evidenced greater microarousals than healthy controls. In participants with IBD, microarousals were associated with lower insomnia and greater depression scores. Within IBD, participants with clinically significant insomnia evidenced trend towards lower sleep efficiency, while self-reported disease activity did not significantly impact findings. Conclusions The methodology of past research may have impacted findings, including the reliance on single-night assessments and limited generalisability. Future research that uses robust, multinight assessments of sleep architecture in large, diverse samples is clearly warranted, as is research exploring the impact of cognitive and behavioural factors on sleep architecture and arousal. Trial registration number [NCT04132024][1]. The data underlying this article cannot be shared publicly due to the privacy of individuals that participated in the study. The data will be shared on reasonable request to the corresponding author. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT04132024&atom=%2Fbmjgast%2F10%2F1%2Fe001249.atom
目标 睡眠不佳是炎症性肠病(IBD)的常见症状,可能与疾病的总体恶化有关。虽然有关睡眠/IBD 的文献越来越多,但这些数据通常都是自我报告的。此外,大部分使用睡眠结构或睡眠深度整体模式的客观测量方法的研究都依赖于单晚评估,其有效性可能存在疑问。设计 作为两阶段临床试验的一部分,我们从达特茅斯-希区柯克医学中心招募了患有 IBD 的参与者和健康对照组。根据美国睡眠医学学会的指南,通过三个晚上的家庭脑电监测对睡眠结构进行评估和评分。结果 我们的样本包括 15 名 IBD 患者和 8 名健康对照者。IBD 患者的精神状况更为复杂,自我报告的失眠、焦虑和抑郁情况更多。与健康对照组相比,IBD 患者有更多的微鼾症。在 IBD 患者中,微焦虑与较低的失眠和较高的抑郁评分相关。在 IBD 患者中,有临床症状的失眠患者的睡眠效率呈下降趋势,而自我报告的疾病活动对研究结果没有显著影响。结论 过去的研究方法可能会影响研究结果,包括依赖单夜评估和有限的普遍性。未来的研究显然有必要在大量不同样本中使用可靠的、多晚睡眠结构评估方法,同时也有必要探索认知和行为因素对睡眠结构和唤醒的影响。试验注册号[NCT04132024][1]。由于涉及参与研究的个人隐私,本文所依据的数据不能公开共享。如有合理要求,我们将与通讯作者共享数据。[1]:/lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT04132024&atom=%2Fbmjgast%2F10%2F1%2Fe001249.atom
{"title":"People with IBD evidence more microarousals during sleep architecture assessments","authors":"Jessica K Salwen-Deremer, Matthew J Reid, Sarah J Westvold, Corey A Siegel, Michael T Smith","doi":"10.1136/bmjgast-2023-001249","DOIUrl":"https://doi.org/10.1136/bmjgast-2023-001249","url":null,"abstract":"Objective Poor sleep is common in inflammatory bowel disease (IBD) and may be associated with overall worse disease outcomes. While the sleep/IBD literature is growing, the data are often self-reported. Further, much of the research using objective measures of sleep architecture, or the overall pattern of sleep depth, rely on single-night assessments, which can be of questionable validity. Design Participants with IBD and healthy controls were recruited from Dartmouth-Hitchcock Medical Center as part of a two-phase clinical trial. Sleep architecture was assessed using three nights of in-home electroencephalographic monitoring and scored according to the American Academy of Sleep Medicine guidelines. Results Our sample included 15 participants with IBD and 8 healthy controls. Participants with IBD were more psychiatrically complex, with more self-reported insomnia, anxiety and depression. Participants with IBD evidenced greater microarousals than healthy controls. In participants with IBD, microarousals were associated with lower insomnia and greater depression scores. Within IBD, participants with clinically significant insomnia evidenced trend towards lower sleep efficiency, while self-reported disease activity did not significantly impact findings. Conclusions The methodology of past research may have impacted findings, including the reliance on single-night assessments and limited generalisability. Future research that uses robust, multinight assessments of sleep architecture in large, diverse samples is clearly warranted, as is research exploring the impact of cognitive and behavioural factors on sleep architecture and arousal. Trial registration number [NCT04132024][1]. The data underlying this article cannot be shared publicly due to the privacy of individuals that participated in the study. The data will be shared on reasonable request to the corresponding author. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT04132024&atom=%2Fbmjgast%2F10%2F1%2Fe001249.atom","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":"19 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139056595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of artificial intelligence in imaging and endoscopy for the diagnosis, monitoring and prognostication of inflammatory bowel disease: a scoping review protocol 人工智能在炎症性肠病的诊断、监测和预后方面的成像和内窥镜检查中的作用:范围审查协议
IF 3.1 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-12-01 DOI: 10.1136/bmjgast-2023-001182
Mallory Chavannes, Lynn Kysh, Mariangela Allocca, Noa Krugliak Cleveland, Michael Todd Dolinger, Tom S Robbins, David T Rubin, Shintaro Sagami, Bram Verstockt, Kerri Novak
Introduction Inflammatory bowel diseases (IBD) are immune-mediated conditions that are increasing in incidence and prevalence worldwide. Their assessment and monitoring are becoming increasingly important, though complex. The best disease control is achieved through tight monitoring of objective inflammatory parameters (such as serum and stool inflammatory markers), cross-sectional imaging and endoscopic assessment. Considering the complexity of the information obtained throughout a patient’s journey, artificial intelligence (AI) provides an ideal adjunct to existing tools to help diagnose, monitor and predict the course of disease of patients with IBD. Therefore, we propose a scoping review assessing AI’s role in diagnosis, monitoring and prognostication tools in patients with IBD. We aim to detect gaps in the literature and address them in future research endeavours. Methods and analysis We will search electronic databases, including Medline, Embase, Cochrane CENTRAL, CINAHL Complete, Web of Science and IEEE Xplore. Two reviewers will independently screen the abstracts and titles first and then perform the full-text review. A third reviewer will resolve any conflict. We will include both observational studies and clinical trials. Study characteristics will be extracted using a data extraction form. The extracted data will be summarised in a tabular format, following the imaging modality theme and the study outcome assessed. The results will have an accompanying narrative review. Ethics and dissemination Considering the nature of the project, ethical review by an institutional review board is not required. The data will be presented at academic conferences, and the final product will be published in a peer-reviewed journal. No data are available.
导言 炎症性肠病(IBD)是由免疫介导的疾病,在全球的发病率和流行率都在不断上升。对这些疾病的评估和监测越来越重要,但也越来越复杂。通过对客观炎症指标(如血清和粪便中的炎症标记物)、横断面成像和内窥镜评估的严密监测,可以达到最佳的疾病控制效果。考虑到在患者整个病程中获取信息的复杂性,人工智能(AI)为现有工具提供了理想的辅助工具,有助于诊断、监测和预测 IBD 患者的病程。因此,我们建议对人工智能在 IBD 患者的诊断、监测和预后工具中的作用进行范围界定。我们的目标是发现文献中的不足,并在未来的研究工作中加以解决。方法与分析 我们将检索电子数据库,包括 Medline、Embase、Cochrane CENTRAL、CINAHL Complete、Web of Science 和 IEEE Xplore。两名审稿人将首先独立筛选摘要和标题,然后进行全文审阅。第三位审稿人将解决任何冲突。我们将同时纳入观察性研究和临床试验。我们将使用数据提取表来提取研究特征。提取的数据将按照成像模式主题和评估的研究结果以表格形式汇总。研究结果将附有叙述性综述。伦理和传播 考虑到该项目的性质,无需由机构审查委员会进行伦理审查。数据将在学术会议上公布,最终成果将在同行评审期刊上发表。暂无数据。
{"title":"Role of artificial intelligence in imaging and endoscopy for the diagnosis, monitoring and prognostication of inflammatory bowel disease: a scoping review protocol","authors":"Mallory Chavannes, Lynn Kysh, Mariangela Allocca, Noa Krugliak Cleveland, Michael Todd Dolinger, Tom S Robbins, David T Rubin, Shintaro Sagami, Bram Verstockt, Kerri Novak","doi":"10.1136/bmjgast-2023-001182","DOIUrl":"https://doi.org/10.1136/bmjgast-2023-001182","url":null,"abstract":"Introduction Inflammatory bowel diseases (IBD) are immune-mediated conditions that are increasing in incidence and prevalence worldwide. Their assessment and monitoring are becoming increasingly important, though complex. The best disease control is achieved through tight monitoring of objective inflammatory parameters (such as serum and stool inflammatory markers), cross-sectional imaging and endoscopic assessment. Considering the complexity of the information obtained throughout a patient’s journey, artificial intelligence (AI) provides an ideal adjunct to existing tools to help diagnose, monitor and predict the course of disease of patients with IBD. Therefore, we propose a scoping review assessing AI’s role in diagnosis, monitoring and prognostication tools in patients with IBD. We aim to detect gaps in the literature and address them in future research endeavours. Methods and analysis We will search electronic databases, including Medline, Embase, Cochrane CENTRAL, CINAHL Complete, Web of Science and IEEE Xplore. Two reviewers will independently screen the abstracts and titles first and then perform the full-text review. A third reviewer will resolve any conflict. We will include both observational studies and clinical trials. Study characteristics will be extracted using a data extraction form. The extracted data will be summarised in a tabular format, following the imaging modality theme and the study outcome assessed. The results will have an accompanying narrative review. Ethics and dissemination Considering the nature of the project, ethical review by an institutional review board is not required. The data will be presented at academic conferences, and the final product will be published in a peer-reviewed journal. No data are available.","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":"196 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138572163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Progression of the FIB-4 index among patients with chronic HCV infection and early liver disease 慢性丙型肝炎病毒感染和早期肝病患者的 FIB-4 指数进展情况
IF 3.1 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-12-01 DOI: 10.1136/bmjgast-2023-001209
Lisette A P Krassenburg, Raoel Maan, Amy Puenpatom, Nicole S Erler, Christoph Welsch, Stijn van Hees, Orlando Cerrhoci, Johannes Vermehren, Robert J de Knegt, Bettina E Hansen, Stefan Zeuzem, Thomas Vanwolleghem, Harry L A Janssen, Robert A de Man, Jordan J Feld, Adriaan J van der Meer
Background and aims Historical paired liver biopsy studies are likely to underestimate current progression of disease in patients with chronic hepatitis C virus (HCV) infection. We aimed to assess liver disease progression according to the non-invasive Fibrosis-4 (FIB-4) index in patients with chronic HCV and early disease. Methods and results Patients diagnosed with chronic HCV and FIB-4 <3.25 from four international liver clinics were included in a retrospective cohort study. Follow-up ended at start of antiviral therapy resulting in sustained virological response, at time of liver transplantation or death. Primary outcome of advanced liver disease was defined as FIB-4 >3.25 during follow-up. Survival analyses were used to assess time to FIB-4 >3.25. In total, 4286 patients were followed for a median of 5.0 (IQR 1.7–9.4) years, during which 41 071 FIB-4 measurements were collected. At baseline, median age was 47 (IQR 39–55) years, 2529 (59.0%) were male, and 2787 (65.0%) patients had a FIB-4 <1.45. Advanced liver disease developed in 821 patients. Overall, 10-year cumulative incidence of advanced disease was 32.1% (95% CI 29.9% to 34.3%). Patients who developed advanced disease showed an exponential FIB-4 increase. Among patients with a presumed date of HCV infection, cumulative incidence of advanced disease increased 7.7-fold from 20 to 40 years as opposed to the first 20 years after HCV infection. Conclusions The rate of advanced liver disease is high among chronic HCV-infected patients with early disease at time of diagnosis, among whom liver disease progression accelerated over time. These results emphasise the need to overcome any limitations with respect to diagnosing and treating all patients with chronic HCV across the globe. Data are available upon reasonable request.
背景和目的 历史上的配对肝活检研究很可能低估了慢性丙型肝炎病毒(HCV)感染患者当前的病情进展。我们旨在根据非侵入性纤维化-4(FIB-4)指数评估慢性丙型肝炎病毒感染者和早期疾病患者的肝病进展情况。方法和结果 在随访期间诊断为慢性 HCV 和 FIB-4 3.25 的患者。采用生存分析评估 FIB-4 >3.25 的时间。共对 4286 名患者进行了中位数为 5.0 年(IQR 1.7-9.4 年)的随访,在此期间共收集了 41071 次 FIB-4 测量数据。基线年龄中位数为 47 岁(IQR 39-55),2529 名患者(59.0%)为男性,2787 名患者(65.0%)的 FIB-4 值小于 1.45。821名患者出现晚期肝病。总体而言,晚期肝病的 10 年累积发病率为 32.1%(95% CI 29.9% 至 34.3%)。晚期肝病患者的 FIB-4 呈指数增长。在推测感染 HCV 日期的患者中,晚期疾病的累积发病率在 20 至 40 年间比感染 HCV 后的前 20 年增加了 7.7 倍。结论 在确诊时病情较早的慢性 HCV 感染者中,晚期肝病的发病率较高,而且随着时间的推移,肝病的进展速度加快。这些结果表明,有必要克服在诊断和治疗全球所有慢性 HCV 患者方面存在的任何局限性。如有合理要求,可提供相关数据。
{"title":"Progression of the FIB-4 index among patients with chronic HCV infection and early liver disease","authors":"Lisette A P Krassenburg, Raoel Maan, Amy Puenpatom, Nicole S Erler, Christoph Welsch, Stijn van Hees, Orlando Cerrhoci, Johannes Vermehren, Robert J de Knegt, Bettina E Hansen, Stefan Zeuzem, Thomas Vanwolleghem, Harry L A Janssen, Robert A de Man, Jordan J Feld, Adriaan J van der Meer","doi":"10.1136/bmjgast-2023-001209","DOIUrl":"https://doi.org/10.1136/bmjgast-2023-001209","url":null,"abstract":"Background and aims Historical paired liver biopsy studies are likely to underestimate current progression of disease in patients with chronic hepatitis C virus (HCV) infection. We aimed to assess liver disease progression according to the non-invasive Fibrosis-4 (FIB-4) index in patients with chronic HCV and early disease. Methods and results Patients diagnosed with chronic HCV and FIB-4 <3.25 from four international liver clinics were included in a retrospective cohort study. Follow-up ended at start of antiviral therapy resulting in sustained virological response, at time of liver transplantation or death. Primary outcome of advanced liver disease was defined as FIB-4 >3.25 during follow-up. Survival analyses were used to assess time to FIB-4 >3.25. In total, 4286 patients were followed for a median of 5.0 (IQR 1.7–9.4) years, during which 41 071 FIB-4 measurements were collected. At baseline, median age was 47 (IQR 39–55) years, 2529 (59.0%) were male, and 2787 (65.0%) patients had a FIB-4 <1.45. Advanced liver disease developed in 821 patients. Overall, 10-year cumulative incidence of advanced disease was 32.1% (95% CI 29.9% to 34.3%). Patients who developed advanced disease showed an exponential FIB-4 increase. Among patients with a presumed date of HCV infection, cumulative incidence of advanced disease increased 7.7-fold from 20 to 40 years as opposed to the first 20 years after HCV infection. Conclusions The rate of advanced liver disease is high among chronic HCV-infected patients with early disease at time of diagnosis, among whom liver disease progression accelerated over time. These results emphasise the need to overcome any limitations with respect to diagnosing and treating all patients with chronic HCV across the globe. Data are available upon reasonable request.","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":"3 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138554832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Complications of colonoscopy: common and rare—recognition, assessment and management 结肠镜检查并发症:常见与罕见--识别、评估与处理
IF 3.1 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-12-01 DOI: 10.1136/bmjgast-2023-001193
William Waddingham, Umair Kamran, Bhaskar Kumar, Nigel J Trudgill, Zacharias P Tsiamoulos, Matthew Banks
An understanding of the potential complications of diagnostic lower gastrointestinal endoscopy is a necessary part of being an independent endoscopist. Creating a culture of safety and prevention of adverse events (AEs) should be part of routine endoscopy practice. Appropriate patient selection for procedures, informed consent, peri-procedure risk assessments and an inclusive team approach, all contribute to preventing AEs. Early recognition, prompt management and transparent communication with patients are essential for the holistic and optimal management of AEs. In this review, we discuss the complications of diagnostic lower gastro-intestinal endoscopy, including their recognition, treatment and prevention.
了解下消化道内窥镜诊断的潜在并发症是成为一名独立内窥镜医师的必要条件。创建安全文化和预防不良事件(AEs)应成为常规内窥镜检查实践的一部分。选择适当的患者进行手术、知情同意、围手术期风险评估和包容性的团队方法,都有助于预防不良事件的发生。早期识别、及时处理并与患者进行透明的沟通对于全面和最佳地处理并发症至关重要。在本综述中,我们将讨论下消化道内窥镜诊断并发症,包括其识别、治疗和预防。
{"title":"Complications of colonoscopy: common and rare—recognition, assessment and management","authors":"William Waddingham, Umair Kamran, Bhaskar Kumar, Nigel J Trudgill, Zacharias P Tsiamoulos, Matthew Banks","doi":"10.1136/bmjgast-2023-001193","DOIUrl":"https://doi.org/10.1136/bmjgast-2023-001193","url":null,"abstract":"An understanding of the potential complications of diagnostic lower gastrointestinal endoscopy is a necessary part of being an independent endoscopist. Creating a culture of safety and prevention of adverse events (AEs) should be part of routine endoscopy practice. Appropriate patient selection for procedures, informed consent, peri-procedure risk assessments and an inclusive team approach, all contribute to preventing AEs. Early recognition, prompt management and transparent communication with patients are essential for the holistic and optimal management of AEs. In this review, we discuss the complications of diagnostic lower gastro-intestinal endoscopy, including their recognition, treatment and prevention.","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":"12 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138554560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating clinical outcomes and prognosis in patients with cirrhosis and portal hypertension: a retrospective observational cohort study. 评估肝硬化和门脉高压患者的临床结果和预后:一项回顾性观察队列研究。
IF 3.1 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-11-29 DOI: 10.1136/bmjgast-2023-001234
Nerissa Hoi Ching Lee, Steven J Kiddle, Shardul Chandankhede, Shubh Agrawal, Daniel M Bean, Phillip R Hunt, Victoria E R Parker, Peter J Greasley, Philip Ambery

Objective: Cirrhosis describes the end-stage of chronic liver disease. Irreversible changes in the liver cause portal hypertension, which can progress to serious complications and death. Only a few studies with small sample sizes have investigated the prognosis of cirrhosis with portal hypertension. We used electronic healthcare records to examine liver-related outcomes in patients with diagnosed/suspected portal hypertension.

Design: This retrospective observational cohort study used secondary health data between 1 January 2017 and 3 December 2020 from the TriNetX Network, a federated electronic healthcare records platform. Three patient groups with cirrhosis and diagnosed/suspected portal hypertension were identified ('most severe', 'moderate severity' and 'least severe'). Outcomes studied individually and as a composite were variceal haemorrhage, hepatic encephalopathy, complications of ascites and recorded mortality up to 24 months.

Results: There were 13 444, 23 299, and 23 836 patients in the most severe, moderate severity and least severe groups, respectively. Mean age was similar across groups; most participants were white. The most common individual outcomes at 24 months were variceal haemorrhage in the most severe group, recorded mortality and hepatic encephalopathy in the moderate severity group, and recorded mortality in the least severe group. Recorded mortality rate was similar across groups. For the composite outcome, cumulative incidence was 59% in the most severe group at 6 months. Alcohol-associated liver disease and metabolic-associated steatohepatitis were significantly associated with the composite outcome across groups.

Conclusion: Our analysis of a large dataset from electronic healthcare records illustrates the poor prognosis of patients with diagnosed/suspected portal hypertension.

目的:肝硬化描述慢性肝病的终末期。肝脏的不可逆变化导致门静脉高压,这可能发展成严重的并发症和死亡。只有少数小样本量的研究探讨了肝硬化合并门静脉高压症的预后。我们使用电子医疗记录来检查诊断或疑似门静脉高压症患者的肝脏相关预后。设计:这项回顾性观察性队列研究使用了来自TriNetX网络(一个联邦电子医疗记录平台)的2017年1月1日至2020年12月3日的二级健康数据。确定了肝硬化和诊断/疑似门脉高压的三组患者(“最严重”、“中度严重”和“最不严重”)。单独研究和综合研究的结果包括静脉曲张出血、肝性脑病、腹水并发症和长达24个月的记录死亡率。结果:重症组13 444例,中度组23 299例,轻重度组23 836例。各组平均年龄相似;大多数参与者是白人。24个月时最常见的个体结局是最严重组的静脉曲张出血,中度严重组记录的死亡率和肝性脑病,最不严重组记录的死亡率。记录的死亡率在各组之间相似。对于综合结果,6个月时最严重组的累积发病率为59%。酒精相关的肝脏疾病和代谢相关的脂肪性肝炎与组间的综合结果显著相关。结论:我们对电子医疗记录的大型数据集的分析表明,诊断或疑似门静脉高压症的患者预后较差。
{"title":"Evaluating clinical outcomes and prognosis in patients with cirrhosis and portal hypertension: a retrospective observational cohort study.","authors":"Nerissa Hoi Ching Lee, Steven J Kiddle, Shardul Chandankhede, Shubh Agrawal, Daniel M Bean, Phillip R Hunt, Victoria E R Parker, Peter J Greasley, Philip Ambery","doi":"10.1136/bmjgast-2023-001234","DOIUrl":"10.1136/bmjgast-2023-001234","url":null,"abstract":"<p><strong>Objective: </strong>Cirrhosis describes the end-stage of chronic liver disease. Irreversible changes in the liver cause portal hypertension, which can progress to serious complications and death. Only a few studies with small sample sizes have investigated the prognosis of cirrhosis with portal hypertension. We used electronic healthcare records to examine liver-related outcomes in patients with diagnosed/suspected portal hypertension.</p><p><strong>Design: </strong>This retrospective observational cohort study used secondary health data between 1 January 2017 and 3 December 2020 from the TriNetX Network, a federated electronic healthcare records platform. Three patient groups with cirrhosis and diagnosed/suspected portal hypertension were identified ('most severe', 'moderate severity' and 'least severe'). Outcomes studied individually and as a composite were variceal haemorrhage, hepatic encephalopathy, complications of ascites and recorded mortality up to 24 months.</p><p><strong>Results: </strong>There were 13 444, 23 299, and 23 836 patients in the most severe, moderate severity and least severe groups, respectively. Mean age was similar across groups; most participants were white. The most common individual outcomes at 24 months were variceal haemorrhage in the most severe group, recorded mortality and hepatic encephalopathy in the moderate severity group, and recorded mortality in the least severe group. Recorded mortality rate was similar across groups. For the composite outcome, cumulative incidence was 59% in the most severe group at 6 months. Alcohol-associated liver disease and metabolic-associated steatohepatitis were significantly associated with the composite outcome across groups.</p><p><strong>Conclusion: </strong>Our analysis of a large dataset from electronic healthcare records illustrates the poor prognosis of patients with diagnosed/suspected portal hypertension.</p>","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":"10 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138457896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interval colorectal cancers after negative faecal immunochemical test in the New Zealand Bowel Screening Pilot. 在新西兰肠道筛查试点中,粪便免疫化学试验阴性后的间隔结直肠癌。
IF 3.1 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-11-24 DOI: 10.1136/bmjgast-2023-001233
Kai Sheng Saw, Kerry Sexton, Paul Frankish, Mike Hulme-Moir, Ian Bissett, Susan Parry

Objective: Evaluate the diagnostic performance of faecal immunochemical test (FIT), identify risk factors for FIT-interval colorectal cancers (FIT-IC) and describe long-term outcomes of participants with colorectal cancers (CRC) in the New Zealand Bowel Screening Pilot (BSP).

Design: From 2012 to 2017, the BSP offered eligible individuals, aged 50-74 years, biennial screening using a quantitative FIT with positivity threshold of 15 µg haemoglobin (Hb)/g faeces. Retrospective review of prospectively maintained data extracted from the BSP Register and New Zealand Cancer Registry identified any CRC reported in participants who returned a definitive FIT result. Further details were obtained from hospital records. FIT-ICs were primary CRC diagnosed within 24 months of a negative FIT. Factors associated with FIT-ICs were identified using logistic regression.

Results: Of 387 215 individuals invited, 57.4% participated with 6.1% returning positive FIT results. Final analysis included 520 CRC, of which 111 (21.3%) met FIT-IC definition. Overall FIT sensitivity for CRC was 78.7% (95% CI=74.9% to 82.1%), specificity was 94.1% (95% CI=94.0% to 94.2%). In 78 (70.3%) participants with FIT-IC, faecal Hb was reported as undetectable. There were no significant associations between FIT-IC and age, sex, ethnicity and deprivation. FIT-ICs were significantly associated with proximal tumour location, late stage at diagnosis, high-grade tumour differentiation and subsequent round screens. Median follow-up time was 74 (2-124) months. FIT-IC had significantly poorer overall survival.

Conclusion: FIT sensitivity in BSP compared favourably to published data. FIT-ICs were more likely to be proximal tumours with poor long-term outcomes. Further lowering of FIT threshold would have minimal impact on FIT-IC.

目的:评估新西兰肠道筛查试点(BSP)中粪便免疫化学试验(FIT)的诊断性能,确定FIT- ic期结直肠癌(FIT- ic)的危险因素,并描述结直肠癌(CRC)参与者的长期结局。设计:从2012年到2017年,BSP为年龄在50-74岁的符合条件的个体提供两年一次的定量FIT筛查,阳性阈值为15µg血红蛋白(Hb)/g粪便。从BSP登记处和新西兰癌症登记处提取的前瞻性数据进行回顾性审查,确定了所有报告的CRC的参与者返回明确的FIT结果。从医院记录中获得了进一步的细节。FIT- ic是在FIT阴性后24个月内诊断出的原发性结直肠癌。使用逻辑回归确定与fiti - ic相关的因素。结果:在被邀请的387 215个人中,57.4%的人参加了比赛,6.1%的人返回了积极的FIT结果。最终分析包括520例结直肠癌,其中111例(21.3%)符合FIT-IC定义。总体FIT对结直肠癌的敏感性为78.7% (95% CI=74.9%至82.1%),特异性为94.1% (95% CI=94.0%至94.2%)。在78名(70.3%)fiti - ic患者中,粪便Hb未被检测到。FIT-IC与年龄、性别、种族和贫困之间没有显著关联。fiti - ic与肿瘤近端位置、晚期诊断、高级别肿瘤分化和随后的圆筛显著相关。中位随访时间为74(2-124)个月。FIT-IC的总生存率明显较低。结论:FIT对BSP的敏感性优于已发表的数据。fit - ic更可能是近端肿瘤,长期预后较差。进一步降低FIT门槛对FIT- ic的影响微乎其微。
{"title":"Interval colorectal cancers after negative faecal immunochemical test in the New Zealand Bowel Screening Pilot.","authors":"Kai Sheng Saw, Kerry Sexton, Paul Frankish, Mike Hulme-Moir, Ian Bissett, Susan Parry","doi":"10.1136/bmjgast-2023-001233","DOIUrl":"10.1136/bmjgast-2023-001233","url":null,"abstract":"<p><strong>Objective: </strong>Evaluate the diagnostic performance of faecal immunochemical test (FIT), identify risk factors for FIT-interval colorectal cancers (FIT-IC) and describe long-term outcomes of participants with colorectal cancers (CRC) in the New Zealand Bowel Screening Pilot (BSP).</p><p><strong>Design: </strong>From 2012 to 2017, the BSP offered eligible individuals, aged 50-74 years, biennial screening using a quantitative FIT with positivity threshold of 15 µg haemoglobin (Hb)/g faeces. Retrospective review of prospectively maintained data extracted from the BSP Register and New Zealand Cancer Registry identified any CRC reported in participants who returned a definitive FIT result. Further details were obtained from hospital records. FIT-ICs were primary CRC diagnosed within 24 months of a negative FIT. Factors associated with FIT-ICs were identified using logistic regression.</p><p><strong>Results: </strong>Of 387 215 individuals invited, 57.4% participated with 6.1% returning positive FIT results. Final analysis included 520 CRC, of which 111 (21.3%) met FIT-IC definition. Overall FIT sensitivity for CRC was 78.7% (95% CI=74.9% to 82.1%), specificity was 94.1% (95% CI=94.0% to 94.2%). In 78 (70.3%) participants with FIT-IC, faecal Hb was reported as undetectable. There were no significant associations between FIT-IC and age, sex, ethnicity and deprivation. FIT-ICs were significantly associated with proximal tumour location, late stage at diagnosis, high-grade tumour differentiation and subsequent round screens. Median follow-up time was 74 (2-124) months. FIT-IC had significantly poorer overall survival.</p><p><strong>Conclusion: </strong>FIT sensitivity in BSP compared favourably to published data. FIT-ICs were more likely to be proximal tumours with poor long-term outcomes. Further lowering of FIT threshold would have minimal impact on FIT-IC.</p>","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":"10 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679982/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138440256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Practical multidisciplinary framework for the assessment and management of patients with unexplained chronic aerodigestive symptoms. 评估和管理不明原因慢性气消化症状患者的实用多学科框架。
IF 3.1 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-11-23 DOI: 10.1136/bmjgast-2022-000883
Nathan Quigley, Sandeep G Mistry, Dipesh H Vasant, Sarju Vasani

Objective: Patients experiencing unexplained chronic throat symptoms (UCTS) are frequently referred to gastroenterology and otolaryngology outpatient departments for investigation. Often despite extensive investigations, an identifiable structural abnormality to account for the symptoms is not found. The objective of this article is to provide a concise appraisal of the evidence-base for current approaches to the assessment and management of UCTS, their clinical outcomes, and related healthcare utilisation.

Design: This multidisciplinary review critically examines the current understanding of aetiological theories and pathophysiological drivers in UCTS and summarises the evidence base underpinning various diagnostic and management approaches.

Results: The evidence gathered from the review suggests that single-specialty approaches to UCTS inadequately capture the substantial heterogeneity and pervasive overlaps among clinical features and biopsychosocial factors and suggests a more unified approach is needed.

Conclusion: Drawing on contemporary insights from the gastrointestinal literature for disorders of gut-brain interaction, this article proposes a refreshed interdisciplinary approach characterised by a positive diagnosis framework and patient-centred therapeutic model. The overarching aim of this approach is to improve patient outcomes and foster collaborative research efforts.

目的:出现不明原因的慢性咽喉症状(UCTS)的患者经常被转介到胃肠病学和耳鼻喉科门诊进行调查。通常,尽管进行了广泛的调查,但没有发现可识别的结构异常来解释这些症状。本文的目的是为目前评估和管理UCTS、其临床结果和相关医疗保健利用的方法提供简明的证据基础评估。设计:这篇多学科综述批判性地考察了目前对UCTS病因学理论和病理生理驱动因素的理解,并总结了支持各种诊断和管理方法的证据基础。结果:从综述中收集的证据表明,单一专业的UCTS方法不能充分捕捉临床特征和生物心理社会因素之间的实质性异质性和普遍重叠,因此需要一种更统一的方法。结论:借鉴当代胃肠文献对肠脑相互作用紊乱的见解,本文提出了一种全新的跨学科方法,其特点是积极的诊断框架和以患者为中心的治疗模式。这种方法的首要目标是改善患者的治疗效果,促进合作研究。
{"title":"Practical multidisciplinary framework for the assessment and management of patients with unexplained chronic aerodigestive symptoms.","authors":"Nathan Quigley, Sandeep G Mistry, Dipesh H Vasant, Sarju Vasani","doi":"10.1136/bmjgast-2022-000883","DOIUrl":"10.1136/bmjgast-2022-000883","url":null,"abstract":"<p><strong>Objective: </strong>Patients experiencing unexplained chronic throat symptoms (UCTS) are frequently referred to gastroenterology and otolaryngology outpatient departments for investigation. Often despite extensive investigations, an identifiable structural abnormality to account for the symptoms is not found. The objective of this article is to provide a concise appraisal of the evidence-base for current approaches to the assessment and management of UCTS, their clinical outcomes, and related healthcare utilisation.</p><p><strong>Design: </strong>This multidisciplinary review critically examines the current understanding of aetiological theories and pathophysiological drivers in UCTS and summarises the evidence base underpinning various diagnostic and management approaches.</p><p><strong>Results: </strong>The evidence gathered from the review suggests that single-specialty approaches to UCTS inadequately capture the substantial heterogeneity and pervasive overlaps among clinical features and biopsychosocial factors and suggests a more unified approach is needed.</p><p><strong>Conclusion: </strong>Drawing on contemporary insights from the gastrointestinal literature for disorders of gut-brain interaction, this article proposes a refreshed interdisciplinary approach characterised by a positive diagnosis framework and patient-centred therapeutic model. The overarching aim of this approach is to improve patient outcomes and foster collaborative research efforts.</p>","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":"10 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668155/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138298414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
BMJ Open Gastroenterology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1